<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892135</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0171</org_study_id>
    <nct_id>NCT03892135</nct_id>
  </id_info>
  <brief_title>Representation and Medication Use in Juvenile Idiopathic Arthritis</brief_title>
  <acronym>RUMAJI</acronym>
  <official_title>Representation and Medication Use in Juvenile Idiopathic Arthritis - RUMAJI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research department, unknowns, Strategic &amp; innovation consulting, Paris (anthropologists)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NORDIC pharma (funding)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the International League of Associations for Rheumatology classification,
      Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of arthritis of unknown
      cause and with onset before 16 years of age, characterized by joint inflammation lasting for
      6 or more weeks. Few studies exist regarding the care experience of children affected by this
      rheumatic condition. On the other hand, methotrexate and biologics constitute the primary
      treatment for children with JIA. As with adults undergoing the same treatment, adherence is
      critical. Difficulties for children to take the drugs have been reported. Notwithstanding, if
      adherence promotion in pediatric chronic conditions has been the subject of recommendations
      with regard to care management, the investigators lack information to understand the grounds
      for adherence specifically in JIA. In order to understand and decipher the parent-child
      adherence mechanisms and practices, the RUMAJI study will be conducted. Indeed, improving the
      relational approach between children and their caregivers as well as unrestricted drug
      adherence involves researching and understanding how appropriation of the disease and
      treatment could be achieved.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">October 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Interview with parents</measure>
    <time_frame>1 day</time_frame>
    <description>Interview with parents to learn about role of parents in the management of juvenile idiopathic arthritis in their children</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interview with children</measure>
    <time_frame>1 day</time_frame>
    <description>Interview with children to learn about role of children in the management of their juvenile idiopathic arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interview with physicians</measure>
    <time_frame>1 day</time_frame>
    <description>Interview with physicians to learn about role of physicians in the management of juvenile idiopathic arthritis</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Physicians</arm_group_label>
    <description>3 paediatricians and 3 rheumatologists</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parents</arm_group_label>
    <description>Parents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children</arm_group_label>
    <description>Children</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interviews with parents of children with juvenile idiopathic arthritis</intervention_name>
    <description>Interviews with parents of children with juvenile idiopathic arthritis</description>
    <arm_group_label>Parents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interviews with children with juvenile idiopathic arthritis</intervention_name>
    <description>Interviews with children with juvenile idiopathic arthritis</description>
    <arm_group_label>Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interviews with Physicians</intervention_name>
    <description>Interviews with Physicians</description>
    <arm_group_label>Physicians</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with JIA and their parents
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  all JIA forms

          -  all treatment type (NSAIDs, MTX, bDMARDs)

        Exclusion criteria:

        - none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-David COHEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Role of parents, children and physician</keyword>
  <keyword>Qualitative</keyword>
  <keyword>Interview</keyword>
  <keyword>Juvenile idiopathic arthritis</keyword>
  <keyword>Adherence</keyword>
  <keyword>mechanisms of adherence in juvenile idiopathic arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

